In a recent open label study of six patients with ATTR and polyneuropathy, lipid nanoparticle (intravenous delivery) of mRNA for Cas9 protein and a single-guide RNA targeting TTR (NTLA-2001) led to a dose-dependent reduction in TTR of up to 87% at the highest dose [7]. The gene discussed is TTR; the disease is polyneuropathy.